438 related articles for article (PubMed ID: 36422293)
1. Natural Products Targeting Hsp90 for a Concurrent Strategy in Glioblastoma and Neurodegeneration.
Mitra S; Dash R; Munni YA; Selsi NJ; Akter N; Uddin MN; Mazumder K; Moon IS
Metabolites; 2022 Nov; 12(11):. PubMed ID: 36422293
[TBL] [Abstract][Full Text] [Related]
2. The novel Hsp90 inhibitor NXD30001 induces tumor regression in a genetically engineered mouse model of glioblastoma multiforme.
Zhu H; Woolfenden S; Bronson RT; Jaffer ZM; Barluenga S; Winssinger N; Rubenstein AE; Chen R; Charest A
Mol Cancer Ther; 2010 Sep; 9(9):2618-26. PubMed ID: 20643786
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of HSP90 as a Strategy to Radiosensitize Glioblastoma: Targeting the DNA Damage Response and Beyond.
Orth M; Albrecht V; Seidl K; Kinzel L; Unger K; Hess J; Kreutzer L; Sun N; Stegen B; Nieto A; Maas J; Winssinger N; Friedl AA; Walch AK; Belka C; Zitzelsberger H; Niyazi M; Lauber K
Front Oncol; 2021; 11():612354. PubMed ID: 33816244
[TBL] [Abstract][Full Text] [Related]
4. A Brain-Penetrating Hsp90 Inhibitor NXD30001 Inhibits Glioblastoma as a Monotherapy or in Combination With Radiation.
Chen H; Gong Y; Ma Y; Thompson RC; Wang J; Cheng Z; Xue L
Front Pharmacol; 2020; 11():974. PubMed ID: 32695001
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Small-Molecule Inhibitors of the HSP90-Calcineurin-NFAT Pathway against Glioblastoma.
Liu Z; Li H; He L; Xiang Y; Tian C; Li C; Tan P; Jing J; Tian Y; Du L; Huang Y; Han L; Li M; Zhou Y
Cell Chem Biol; 2019 Mar; 26(3):352-365.e7. PubMed ID: 30639261
[TBL] [Abstract][Full Text] [Related]
6. The Therapeutic Potential of Targeting Hsp90-Cdc37 Interactions in Several Diseases.
Zhang X; Li S; Li Z; Cheng L; Liu Z; Wang C
Curr Drug Targets; 2022; 23(10):1023-1038. PubMed ID: 35400341
[TBL] [Abstract][Full Text] [Related]
7. Heat shock protein 90 in neurodegenerative diseases.
Luo W; Sun W; Taldone T; Rodina A; Chiosis G
Mol Neurodegener; 2010 Jun; 5():24. PubMed ID: 20525284
[TBL] [Abstract][Full Text] [Related]
8. Advances in HSP27 and HSP90-targeting strategies for glioblastoma.
van Ommeren R; Staudt MD; Xu H; Hebb MO
J Neurooncol; 2016 Apr; 127(2):209-19. PubMed ID: 26842818
[TBL] [Abstract][Full Text] [Related]
9. Targeting the Hsp90-Cdc37-client protein interaction to disrupt Hsp90 chaperone machinery.
Li T; Jiang HL; Tong YG; Lu JJ
J Hematol Oncol; 2018 Apr; 11(1):59. PubMed ID: 29699578
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells.
Sauvageot CM; Weatherbee JL; Kesari S; Winters SE; Barnes J; Dellagatta J; Ramakrishna NR; Stiles CD; Kung AL; Kieran MW; Wen PY
Neuro Oncol; 2009 Apr; 11(2):109-21. PubMed ID: 18682579
[TBL] [Abstract][Full Text] [Related]
11. HSP27 knockdown produces synergistic induction of apoptosis by HSP90 and kinase inhibitors in glioblastoma multiforme.
Belkacemi L; Hebb MO
Anticancer Res; 2014 Sep; 34(9):4915-27. PubMed ID: 25202074
[TBL] [Abstract][Full Text] [Related]
12. Interplay between the Hsp90 Chaperone and the HslVU Protease To Regulate the Level of an Essential Protein in Shewanella oneidensis.
Honoré FA; Maillot NJ; Méjean V; Genest O
mBio; 2019 May; 10(3):. PubMed ID: 31088919
[TBL] [Abstract][Full Text] [Related]
13. A novel extracellular Hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasion.
Gopal U; Bohonowych JE; Lema-Tome C; Liu A; Garrett-Mayer E; Wang B; Isaacs JS
PLoS One; 2011 Mar; 6(3):e17649. PubMed ID: 21408136
[TBL] [Abstract][Full Text] [Related]
14. The disruption of protein-protein interactions with co-chaperones and client substrates as a strategy towards Hsp90 inhibition.
Serwetnyk MA; Blagg BSJ
Acta Pharm Sin B; 2021 Jun; 11(6):1446-1468. PubMed ID: 34221862
[TBL] [Abstract][Full Text] [Related]
15. The stress response: implications for the clinical development of hsp90 inhibitors.
Whitesell L; Bagatell R; Falsey R
Curr Cancer Drug Targets; 2003 Oct; 3(5):349-58. PubMed ID: 14529386
[TBL] [Abstract][Full Text] [Related]
16. Boosting Natural Killer Cell Therapies in Glioblastoma Multiforme Using Supramolecular Cationic Inhibitors of Heat Shock Protein 90.
Saha T; van Vliet AA; Cui C; Macias JJ; Kulkarni A; Pham LN; Lawler S; Spanholtz J; Georgoudaki AM; Duru AD; Goldman A
Front Mol Biosci; 2021; 8():754443. PubMed ID: 34926577
[TBL] [Abstract][Full Text] [Related]
17. Folding or holding?-Hsp70 and Hsp90 chaperoning of misfolded proteins in neurodegenerative disease.
Rutledge BS; Choy WY; Duennwald ML
J Biol Chem; 2022 May; 298(5):101905. PubMed ID: 35398094
[TBL] [Abstract][Full Text] [Related]
18. Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells.
Fu J; Koul D; Yao J; Wang S; Yuan Y; Colman H; Sulman EP; Lang FF; Yung WK
Cancer Res; 2013 May; 73(10):3062-74. PubMed ID: 23492364
[TBL] [Abstract][Full Text] [Related]
19. Low co-expression of epidermal growth factor receptor and its chaperone heat shock protein 90 is associated with worse prognosis in primary glioblastoma, IDH-wild-type.
Sartori E; Langer R; Vassella E; Hewer E; Schucht P; Zlobec I; Berezowska S
Oncol Rep; 2017 Oct; 38(4):2394-2400. PubMed ID: 28765916
[TBL] [Abstract][Full Text] [Related]
20. Heat shock protein 90: the cancer chaperone.
Neckers L
J Biosci; 2007 Apr; 32(3):517-30. PubMed ID: 17536171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
